SCHEMBL6948291

SCHEMBL6948291

Cc1occc1SC=CC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 3/20 0.41
MASP2 O00187 1/20 0.38
F2 P00734 1/20 0.38
LMNA P02545 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NPSR1 Q6W5P4 3/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
TP53 P04637 1/20 0.35
HDAC3 O15379 1/20 0.34
TNKS O95271 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948288 1.00 HCAR2 (0.41) HCAR2MASP2F2LMNAKDM4E
SCHEMBL7463653 0.86 ICAM1 (0.38) HCAR2LMNAKDM4EALDH1A1NPSR1
SCHEMBL6684034 0.86 ICAM1 (0.38) HCAR2LMNAKDM4EALDH1A1NPSR1
SCHEMBL18905887 0.79 MAPT (0.54) LMNAALDH1A1NPSR1KMT2AMAPT
SCHEMBL6832586 0.76 HCAR2 (0.53) HCAR2MASP2F2LMNAKDM4E
SCHEMBL6832587 0.76 HCAR2 (0.53) HCAR2MASP2F2LMNAKDM4E
SCHEMBL6946687 0.73 NPSR1 (0.42) HCAR2LMNAALDH1A1NPSR1KMT2A
SCHEMBL6946681 0.73 NPSR1 (0.42) HCAR2LMNAALDH1A1NPSR1KMT2A
SCHEMBL5989665 0.72
SCHEMBL921135 0.69 CA12 (0.41) LMNAKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed